Researcher.Life Logo

Alzheimer's Research and Therapy : Impact Factor & More

eISSN: 1758-9193pISSN: 1758-9193
JournalOpen Access

Key Metrics

CiteScore
9
Eigenfactor
0.01 - 0.05
Impact Factor
5 - 10
Scite Index
0.89 5-Year SI
SJR
Q1Neurology
SNIP
1
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Alzheimer's Research and Therapy

Alzheimer's Research and Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher Springer Nature
Language English
Frequency Continuous publication
Article Processing ChargesGBP 2390 | USD 3590
Publication Time16
Editorial Review ProcessPeer review
General Details
LanguageEnglish
Society/Institute/SponsorAlzheimer's Disease International
FrequencyContinuous publication
Publication Start Year2009
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 16
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessPeer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC0
OA statementVisit website
View less

Planning to publish in Alzheimer's Research and Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Alzheimer's Research and Therapy

Metabolic parameter variability, brain structure, perfusion, and cognition: a population-based study.
  • 20 May 2026
  • Alzheimer's research & therapy
Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial.
  • 19 May 2026
  • Alzheimer's research & therapy
Clarifying comparative claims in digital cognitive assessment: a matters arising on multimodal detection of cognitive impairment and amyloid positivity.
  • 19 May 2026
  • Alzheimer's research & therapy
Re: Clarifying comparative claims in digital cognitive assessment: Assessing concurrent validity in a shared cohort.
  • 19 May 2026
  • Alzheimer's research & therapy
TNF inhibition differentially impacts regional Abeta immunotherapy efficacy in the humanized hAbSAA mouse model.
  • 19 May 2026
  • Alzheimer's research & therapy
Willingness and barriers to blood-based biomarker testing of Alzheimer's disease in the general population in the Czech Republic.
  • 18 May 2026
  • Alzheimer's research & therapy
Metabolic parameter variability, brain structure, perfusion, and cognition: a population-based study.
  • 20 May 2026
  • Alzheimer's research & therapy
Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial.
  • 19 May 2026
  • Alzheimer's research & therapy
Clarifying comparative claims in digital cognitive assessment: a matters arising on multimodal detection of cognitive impairment and amyloid positivity.
  • 19 May 2026
  • Alzheimer's research & therapy
Re: Clarifying comparative claims in digital cognitive assessment: Assessing concurrent validity in a shared cohort.
  • 19 May 2026
  • Alzheimer's research & therapy
TNF inhibition differentially impacts regional Abeta immunotherapy efficacy in the humanized hAbSAA mouse model.
  • 19 May 2026
  • Alzheimer's research & therapy
Willingness and barriers to blood-based biomarker testing of Alzheimer's disease in the general population in the Czech Republic.
  • 18 May 2026
  • Alzheimer's research & therapy

FAQs on Alzheimer's Research and Therapy